FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
Source: kpvi.com
📰 Shows High Potency News
Shows High Potency News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Shows High Potency. Real-time updates on events, politics, business and more.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...
Source: prnewswire.com
Targeting DLL-3 for a variety of potential lung cancer therapies
In this article, ACROBiosystems demonstrates how DLL-3 could become a potential target for a variety of lung cancer therapies.
Susan Winandy Nan Fang Alex Smith Martin Peter Proceedings Of The National Academy Sci Journal Of Southern Medical University
Source: news-medical.net